LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarker FR+CTC Explored for Breast Cancer Diagnosis

By LabMedica International staff writers
Posted on 30 Dec 2021
Print article
Image: A colored scanning electron micrograph (SEM) of a breast cancer cell (Photo courtesy of Case Western Reserve University School)
Image: A colored scanning electron micrograph (SEM) of a breast cancer cell (Photo courtesy of Case Western Reserve University School)
The prognosis of breast cancer is dramatically improved owing to progress on the early diagnosis and effective therapy, and the survivor number is higher than any other types of cancers. However, the number of new breast cancer cases reached 2.26 million in 2020, accounted for 11.7% of all new tumor cases.

Folate receptor (FR) is a glycosylated phosphatidylinositol-coupled protein with high affinity and endocytosis and transport capacity for its natural ligand folic acid. It is a cell surface protein that has been proven to be an ideal tumor marker for non-small cell lung cancer. The clinical significance of folate receptor-positive circulating tumor cells (FR+CTC) has been explored.

Clinical Laboratorians at the Renmin Hospital of Wuhan University (Wuhan, China) enrolled in a study 60 breast cancer female patients with a mean age of 52 years (range, 27–75 years) and 32 healthy controls with an age of 52 (range, 40–66 years), from January 2019 to January 2021. The diagnosis for the patients was confirmed by cytology or histopathology. Peripheral blood was collected for isolation of circulating tumor cells (CTC) on the diagnosis in all patients of the cohort. The 27 patients underwent radical mastectomy, and the peripheral blood was also collected in two weeks after the operation.

Circulating tumor cells was isolated with folate receptor-positive (FR+) CTC isolation method using CytoploRare kit (GenoSaber Biotech Co., Ltd., Shanghai, China). The method includes negative enrichment of FR+ circulating tumor cells with immunomagnetic beads to deplete leukocytes first, then CTC level was quantitated by ligand-targeted PCR. First, leukocytes and mononuclear macrophages were removed by anti-CD45 and anti-CD14 magnetic beads. Then, the cells were activated and washed to free up the folate binding site. The carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), and cancer antigen 153 (CA153) were measured by chemiluminescent immunoassay.

The investigators reported that the levels of FR+CTC were significantly higher in breast cancer patients compared with healthy controls. The levels of FR+CTC in breast cancer patients and healthy people were 10.95 (7.28–14.15) FU/3 mL and 6.93 (5.46–8.19) FU/3 mL, respectively. The detection rate of FR+CTC was decreased in 19 of 27 patients underwent the surgery in two weeks post-operation compared with pre-operation; statistical analysis showed the difference was significant. They also found that the combination of FR+CTC, CEA, CA125, and CA153 can significantly improve the diagnostic efficiency for breast cancer.

The authors concluded that the detection of FR+CTCs in peripheral blood is simple, noninvasive methods with high sensitivity and specificity. It can be used as a potential biomarker for auxiliary diagnosis and early detection in breast cancer patients. The study was published on December 17, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Renmin Hospital of Wuhan University
GenoSaber Biotech Co., Ltd.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more